[Edaily Reporter Kim Ji-wan] #BLPharmTech announced on the 18th that it will participate in BIO USA 2026, the world’s largest biotech partnering event held in San Diego, USA, to introduce its next-generation Molecular Glue Degrader (MGD)-based anti-cancer pipeline and platform expansion strategy to global pharmaceutical and biotech companies.

At this event, BL PharmTech plans to hold partnering meetings with global companies and research institutions in the fields of antibodies, ADCs, and targeted protein degradation (TPD).

The company plans to hold wide-ranging discussions centered on its core pipeline, ML301, covering global licensing, joint research, and the potential for integrating new antibody-based modalities.

ML301 is a molecular glue degrader candidate targeting refractory solid tumors that rely on the Alternative Lengthening of Telomeres (ALT) mechanism.

ALT-positive tumors represent an area of unmet medical need where existing treatment options are limited. Through ML301, BL Pharmtech aims to achieve anticancer effects that differentiate it from existing small-molecule inhibitors or PROTAC approaches by selectively degrading disease-causing proteins essential for cancer cell survival.

According to the company, ML301 has demonstrated anticancer activity and the potential to inhibit tumor growth in cell-based studies and animal model efficacy evaluations targeting ALT-positive cancer cells.

In particular, the molecular adhesive approach is expected to offer advantages such as the potential for developing an oral new drug based on its relatively low molecular weight and catalytic properties, sustained degradation of target proteins, and a reduced risk of resistance development.

Through its partnering materials for BIO USA 2026, BL Pharmtech will present not only the potential for ML301 as a standalone small-molecule anticancer drug but also the platform’s scalability.

Notably, the company plans to introduce the ML303 strategy—which leverages the degrader payload characteristics of ML301 to expand into next-generation ADCs and Degrader-Antibody Conjugates (DACs)—and the ML304 strategy, which combines blood-brain barrier (BBB) shuttle antibody technology to expand into the central nervous system (CNS) disease area, including ALT-positive brain tumors.

In particular, ML303 is being evaluated as a next-generation smart payload strategy designed to address the limitations of existing ADC therapies, such as resistance and toxicity.

Since degrader-based payloads catalyze the removal of target proteins, they are expected to deliver sustained therapeutic effects even in environments with low target expression; they can also be expanded to various solid tumor indications depending on the combination of antibody, linker, and payload.

Through this event, BL Pharmtech plans to propose phased collaboration strategies, including signing non-disclosure agreements (NDAs) for initial technology reviews, sharing preclinical data packages, facilitating internal validation by partners via material transfer agreements (MTAs), and discussing joint development or licensing structures.

The company’s strategy is to accelerate the preclinical development of ML301 through collaboration with global partners and to solidify the commercialization potential of its follow-on pipeline by combining it with antibody engineering-based technologies such as ADCs and BBB shuttles.

A BL PharmTech official stated, “BIO USA 2026 is a crucial partnering event where we can directly explain the scientific differentiation and global expansion potential of ML301,” adding, “Starting with a clear biomarker-based indication—ALT-positive cancer—we will actively seek joint research opportunities that can be integrated with various antibody technologies, such as ADCs, DACs, and BBB shuttle antibodies.”